Pre-dosing NHL patients with HH1 anti-CD37 antibody before Betalutin® increases its pharmacokinetic exposure and reduces its haematological toxicity

On June 10, 2016 Nordic Nanovector ASA (OSE: NANO) reported that pharmacokinetic analyses of a clinical study in patients with non-Hodgkin lymphoma (NHL) demonstrate that pre-dosing with the anti-CD37 antibody HH1, prior to injection with Betalutin (177Lu-HH1) significantly increases the pharmacokinetic exposure of NHL tumour cells to Betalutin (p < 0.001) while protecting against haematological side effects (Press release, Nordic Nanovector, JUN 10, 2016, View Source [SID:1234513205]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, part of the ongoing Lymrit 37-01 Phase 1/2 trial of Betalutin in NHL, evaluated 13 NHL patients who received different doses of Betalutin either with or without HH1 pre-dosing. The analysis will be presented in an ePoster at the 21st Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) (Copenhagen, Denmark, 9-12 June) by Dr Arne Kolstad, a senior consultant in medical oncology and radiotherapy at Oslo University Hospital, Radiumhospitalet and a member of Nordic Nanovector’s Scientific Advisory Board. The poster is available here EHA (Free EHA Whitepaper) 2016 and at www.nordicnanovector.com in the section: Product Info/Scientific Posters.

Jostein Dahle, Nordic Nanovector CSO, commented: "The results presented in this poster continue to support our hypothesis that pre-dosing provides a protective effect on healthy tissues when used prior to Betalutin treatment."

The Lymrit 37-01 study is a Phase 1/2 open label, single injection ascending dose study investigating three dose levels of Betalutin and different pre-dosing regimens in patients with relapsed NHL with the aim of identifying an optimal dose regimen to take into the Phase 2 PARADIGME study, which is expected to start in 2H 2017.